Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China. On September 2nd, Bristol Myers Squibb China announced that the original tumor treatment drug Abraxane (injectable paclitaxel [albumin bound], abbreviated as "albumin paclitaxel", Kaisu) has been officially launched in China. Abraxane is a global original product of albumin paclitaxel, which is approved in China to be used in combination with gemcitabine as a first-line treatment for metastatic pancreatic cancer, as well as for the treatment of metastatic breast cancer that fails in combination chemotherapy or breast cancer patients who relapse within 6 months after adjuvant chemotherapy.